Related references
Note: Only part of the references are listed.Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis
Aisling O'Neill et al.
PSYCHOLOGICAL MEDICINE (2021)
Cannabidiol modulation of hippocampal glutamate in early psychosis
Aisling O'Neill et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2021)
Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
F. Markus Leweke et al.
FRONTIERS IN PHARMACOLOGY (2021)
Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
Francesco Bartoli et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies
Julie Schoevers et al.
CURRENT OPINION IN PSYCHIATRY (2020)
Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: A systematic review with a risk of bias assessment
Maykel Farag Ghabrash et al.
PSYCHIATRY RESEARCH (2020)
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
Albert Batalla et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
Stefania Bonaccorso et al.
NEUROTOXICOLOGY (2019)
Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis
Robin Wilson et al.
TRANSLATIONAL PSYCHIATRY (2019)
A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects
Nadia Solowij et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2019)
Cannabidiol as a potential treatment for psychosis
Cathy Davies et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2019)
Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Delta(9)-Tetrahydrocannabinol
Douglas L. Boggs et al.
NEUROPSYCHOPHARMACOLOGY (2018)
US Epidemiology of Cannabis Use and Associated Problems
Deborah S. Hasin
NEUROPSYCHOPHARMACOLOGY (2018)
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
Philip McGuire et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders
Musa Basseer Sami et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
Risks and Benefits of Marijuana Use A National Survey of US Adults
Salomeh Keyhani et al.
ANNALS OF INTERNAL MEDICINE (2018)
Understanding marijuana's effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: A pilot investigation
Susan Whitfield-Gabrieli et al.
SCHIZOPHRENIA RESEARCH (2018)
Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis A Randomized Clinical Trial
Sagnik Bhattacharyya et al.
JAMA PSYCHIATRY (2018)
A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains
L. Cinnamon Bidwell et al.
CANNABIS AND CANNABINOID RESEARCH (2018)
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
Ashleigh L. Osborne et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2017)
Symptomatic and functional outcomes of substance use disorder persistence 2 years after admission to a first-episode psychosis program
Amal Abdel-Baki et al.
PSYCHIATRY RESEARCH (2017)
Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers
Shanna Babalonis et al.
DRUG AND ALCOHOL DEPENDENCE (2017)
Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis
Margaret Haney et al.
NEUROPSYCHOPHARMACOLOGY (2016)
Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III
Deborah S. Hasin et al.
AMERICAN JOURNAL OF PSYCHIATRY (2016)
Human Laboratory Studies on Cannabinoids and Psychosis
Mohamed Sherif et al.
BIOLOGICAL PSYCHIATRY (2016)
Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States
Mahmoud A. ElSohly et al.
BIOLOGICAL PSYCHIATRY (2016)
Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis
Arianna Marconi et al.
SCHIZOPHRENIA BULLETIN (2016)
Cannabis and tolerance: acute drug impairment as a function of cannabis use history (vol 6, 26843, 2016)
J. G. Ramaekers et al.
SCIENTIFIC REPORTS (2016)
Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC
Adina S. Fischer et al.
SCHIZOPHRENIA RESEARCH (2014)
A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation
Nick Meader et al.
SYSTEMATIC REVIEWS (2014)
Cannabis use and vulnerability for psychosis in early adolescence-a TRAILS study
Merel F. H. Griffith-Lendering et al.
ADDICTION (2013)
Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint
Marie Fabritius et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2013)
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Amir Englund et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
Acute effects of THC on time perception in frequent and infrequent cannabis users
R. Andrew Sewell et al.
PSYCHOPHARMACOLOGY (2013)
Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
Kyoko Higashi et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2013)
The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample
Murat Yuecel et al.
SCHIZOPHRENIA BULLETIN (2012)
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. M. Leweke et al.
TRANSLATIONAL PSYCHIATRY (2012)
Brain Network Connectivity in Individuals with Schizophrenia and Their Siblings
Grega Repovs et al.
BIOLOGICAL PSYCHIATRY (2011)
Neural correlates of cognitive impairment in schizophrenia
Jordi Ortiz-Gil et al.
BRITISH JOURNAL OF PSYCHIATRY (2011)
GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias)
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
How Prevalent Are Anxiety Disorders in Schizophrenia? A Meta-Analysis and Critical Review on a Significant Association
Amelie M. Achim et al.
SCHIZOPHRENIA BULLETIN (2011)
Examining a Cognitive Model of Persecutory Ideation in the Daily Life of People With Schizophrenia: A Computerized Experience Sampling Study
Dror Ben-Zeev et al.
SCHIZOPHRENIA BULLETIN (2011)
Cannabis with high cannabidiol content is associated with fewer psychotic experiences
Christian D. Schubart et al.
SCHIZOPHRENIA RESEARCH (2011)
Functional resting-state networks are differentially affected in schizophrenia
Neil D. Woodward et al.
SCHIZOPHRENIA RESEARCH (2011)
Who Are Medical Marijuana Patients? Population Characteristics from Nine California Assessment Clinics
Craig Reinarman et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder
Serge Sevy et al.
ACTA PSYCHIATRICA SCANDINAVICA (2010)
Psychosis reactivity to cannabis use in daily life: an experience sampling study
Cecile Henquet et al.
BRITISH JOURNAL OF PSYCHIATRY (2010)
Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
Sagnik Bhattacharyya et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
Jaime E. C. Hallak et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2010)
Rate of Cannabis Use Disorders in Clinical Samples of Patients With Schizophrenia: A Meta-analysis
Johanna Koskinen et al.
SCHIZOPHRENIA BULLETIN (2010)
Alterations in Functional Activation in Euthymic Bipolar Disorder and Schizophrenia During a Working Memory Task
Liberty S. Hamilton et al.
HUMAN BRAIN MAPPING (2009)
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
Susan Whitfield-Gabrieli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning
P. D. Morrison et al.
PSYCHOLOGICAL MEDICINE (2009)
Psychiatric Comorbidities and Schizophrenia
Peter F. Buckley et al.
SCHIZOPHRENIA BULLETIN (2009)
Association of cannabis use with prodromal symptoms of psychosis in adolescence
Jouko Miettunen et al.
BRITISH JOURNAL OF PSYCHIATRY (2008)
Effects of cannabis use on outcomes of psychotic disorders: systematic review
Stanley Zammit et al.
BRITISH JOURNAL OF PSYCHIATRY (2008)
Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint
Stefan W. Toennes et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2008)
Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis
Deepak Cyril D'Souza et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Reward processing in schizophrenia: A deficit in the representation of value
James M. Gold et al.
SCHIZOPHRENIA BULLETIN (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder
P. A. Ringen et al.
PSYCHOLOGICAL MEDICINE (2008)
Substance abuse and schizophrenia: Pharmacotherapeutic intervention
Alan I. Green et al.
JOURNAL OF SUBSTANCE ABUSE TREATMENT (2008)
Functional disintegration in paranoid schizophrenia using resting-state fMRI
Yuan Zhou et al.
SCHIZOPHRENIA RESEARCH (2007)
Substance abuse and the management of medication nonadherence in schizophrenia
Joshua Wilk et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2006)
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
AW Zuardi et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2006)
Cannabis use and misuse prevalence among people with psychosis
B Green et al.
BRITISH JOURNAL OF PSYCHIATRY (2005)
The environment and schizophrenia: The role of cannabis use
C Henquet et al.
SCHIZOPHRENIA BULLETIN (2005)
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
DC D'Souza et al.
BIOLOGICAL PSYCHIATRY (2005)
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis
DC D'Souza et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Early adolescent cannabis exposure and positive and negative dimensions of psychosis
NC Stefanis et al.
ADDICTION (2004)
The use of the Simpson Angus Scale for the assessment of movement disorder: A training guide
CJ Hawley et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2003)
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study
L Arseneault et al.
BRITISH MEDICAL JOURNAL (2002)
Electrodermically nonresponsive schizophrenia patients make more errors in the Stroop Color Word Test, indicating selective attention deficit
EZ Lopes-Machado et al.
SCHIZOPHRENIA BULLETIN (2002)
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
T Bisogno et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Different effects of nabilone and cannabidiol on binocular depth inversion in man
FM Leweke et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2000)
Substance use disorder in hospitalized severely mentally ill psychiatric patients: Prevalence, correlates, and subgroups
KT Mueser et al.
SCHIZOPHRENIA BULLETIN (2000)
Share Paper
